For the quarter ending 2026-03-31, DYN had -$140,250K decrease in cash & cash equivalents over the period. -$145,143K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -120,854 | -111,955 | -108,040 | -226,219 |
| Depreciation and amortization expense | - | - | - | 1,005 |
| Stock-based compensation expense | 13,081 | 11,226 | 11,082 | 23,543 |
| Loss (gain) on sale of marketable securities | - | -16 | 0 | -14 |
| Depreciation and amortization expense | 550 | 521 | 528 | 1,000 |
| Non-cash lease expense | 116 | 35 | 96 | 32 |
| Non-cash interest expense | 79 | 56 | 60 | 2 |
| Accretion of premium on marketable securities | -271 | -388 | -368 | -1,079 |
| Gain on sale of marketable securities | -30 | - | - | - |
| Loss on disposal of property and equipment | -30 | 0 | 0 | -95 |
| Prepaid expenses and other current assets | 32,847 | 2,198 | -389 | -2,795 |
| Other non-current assets | -28 | -350 | 12,991 | - |
| Accounts payable and other liabilities | -4,804 | -9,463 | 18,470 | -756 |
| Net cash used in operating activities | -144,922 | -111,832 | -90,779 | -200,596 |
| Purchases of property and equipment | 221 | 484 | 395 | 1,041 |
| Advance payment for long-lead equipment | - | 0 | 18,790 | - |
| Purchases of marketable securities | 64,278 | 26,711 | 46,920 | 106,903 |
| Maturities of marketable securities | 33,459 | 18,795 | 28,139 | 107,708 |
| Sales of marketable securities | 28,648 | 9,382 | 1 | 8,468 |
| Net cash used in investing activities | -2,392 | 982 | -37,965 | 8,232 |
| Proceeds from exercise of stock options | 1,311 | 3,366 | 2,073 | 2,560 |
| Proceeds from issuance of long-term debt, net of issuance costs paid | - | 49,454 | 0 | 98,802 |
| Payment of debt issuance costs | 30 | 9 | 549 | - |
| Payment of issuance costs from public offering of common stock | 424 | - | - | - |
| Proceeds from vendor financing arrangement | 6,786 | - | - | - |
| Proceeds from issuance of common stock in public offering, net of issuance costs | - | 378,154 | 215,803 | 0 |
| Repayments under vendor financing arrangement | 579 | - | - | - |
| Proceeds from issuance of common stock in at-the-market offering, net of issuance costs | 0 | 0 | 0 | 140,653 |
| Net cash provided by financing activities | 7,064 | 430,965 | 217,327 | 242,015 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -140,250 | 320,115 | 88,583 | 49,651 |
| Cash, cash equivalents and restricted cash, beginning of period | 895,740 | 575,625 | 437,391 | - |
| Cash, cash equivalents and restricted cash, end of period | 755,490 | 895,740 | 575,625 | - |
Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics, Inc. (DYN)